Dolatsinh Zala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dolatsinh Zala has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Douglas J. H. Shyu
Department of Biological Science and Technology, National Pingtung University of Science and Technology, Pingtung 912301, Taiwan
1 shared publication - Mustafa Vohra
Department of Medical Laboratory Science, Lovely Professional University
1 shared publication - Pravin Dudhagara
Department of Biosciences, Veer Narmad South Gujarat University, India
1 shared publication - Rajesh Patel
Department of Biosciences, Veer Narmad South Gujarat University, India
1 shared publication - Rajeshkumar Ghemarbhai Chaudhari
School of Applied Sciences and Technology Gujarat Technology University Chandkheda 382 424 Ahmedabad Gujarat India
1 shared publication - Vikram Khan
Directorate of Medical & Health Services, UT of Dadra & Nagar Haveli and Daman Diu, Silvassa, India
1 shared publication
Latest Publications
- Open Access
- 7 August 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (8) , 2030
Whole Genome Sequencing and Pan-Genomic Analysis of Multidrug-Resistant Vibrio cholerae VC01 Isolated from a Clinical Sample
Cholera, a disease caused by the Vibrio cholerae bacteria, threatens public health worldwide. The organism mentioned above has a significant historical record of being identified as a prominent aquatic environmental pollutant capable of adapting its phenotypic and genotypic traits to react to host patients effectively. This study aims to elucidate the heterogeneity of the sporadic clinical strain of V. cholerae VC01 among patients residing in Silvasa. The study involved conducting whole-genome sequencing of the isolate obtained from patients exhibiting symptoms, including those not commonly observed in clinical practice. The strain was initially identified through a combination of biochemical analysis, microscopy, and 16s rRNA-based identification, followed by type strain-based identification. The investigation demonstrated the existence of various genetic alterations and resistance profiles against multiple drugs, particularly chloramphenicol (catB9), florfenicol (floR), oxytetracycline (tet(34)), sulfonamide (sul2), and Trimethoprim (dfrA1). The pan-genomic analysis indicated that 1099 distinct clusters were detected within the genome sequences of recent isolates worldwide. The present study helps to establish a correlation between the mutation and the coexistence of antimicrobial resistance toward current treatment.
- 7 August 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (8) , 2030
Open AccessWhole Genome Sequencing and Pan-Genomic Analysis of Multidrug-Resistant Vibrio cholerae VC01 Isolated from a Clinical Sample
Cholera, a disease caused by the Vibrio cholerae bacteria, threatens public health worldwide. The organism mentioned above has a significant historical record of being identified as a prominent aquatic environmental pollutant capable of adapting its phenotypic and genotypic traits to react to host patients effectively. This study aims to elucidate the heterogeneity of the sporadic clinical strain of V. cholerae VC01 among patients residing in Silvasa. The study involved conducting whole-genome sequencing of the isolate obtained from patients exhibiting symptoms, including those not commonly observed in clinical practice. The strain was initially identified through a combination of biochemical analysis, microscopy, and 16s rRNA-based identification, followed by type strain-based identification. The investigation demonstrated the existence of various genetic alterations and resistance profiles against multiple drugs, particularly chloramphenicol (catB9), florfenicol (floR), oxytetracycline (tet(34)), sulfonamide (sul2), and Trimethoprim (dfrA1). The pan-genomic analysis indicated that 1099 distinct clusters were detected within the genome sequences of recent isolates worldwide. The present study helps to establish a correlation between the mutation and the coexistence of antimicrobial resistance toward current treatment.